Darzalex 400 mg Injection | Daratumumab for Multiple Myeloma

Darzalex 400 mg Injection is a prescription oncology medicine containing daratumumab, a monoclonal antibody used in the treatment of multiple myeloma, a cancer affecting plasma cells in the bone marrow. Daratumumab targets CD38, a protein expressed on the surface of multiple myeloma cells.

Darzalex is administered intravenously by qualified healthcare professionals in an appropriate clinical setting. The 400 mg presentation is commonly supplied as a 20 mL concentrate containing 20 mg/mL daratumumab; product presentation and availability should be verified against the applicable local product label.

Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical product information and supports enquiries regarding medicine availability and supply, subject to applicable regulatory requirements and market authorization.

Uses and Potential Benefits of Darzalex 400 mg

Darzalex is used in specialist oncology treatment protocols for eligible adults with multiple myeloma. Depending on the patient's condition, treatment history and local approved prescribing information, daratumumab may be prescribed alone in specific settings or in combination with other medicines.

Potential clinical benefits include:

Targeted treatment approach: Daratumumab binds to CD38 and helps the immune system identify and eliminate certain cancer cells.

Treatment regimen options: It can be incorporated into approved combination therapies for newly diagnosed or relapsed and refractory multiple myeloma.

Specialist-directed cancer care: It provides an additional treatment option for eligible patients under the supervision of a qualified hematologist or oncologist.

Treatment response varies between patients. Darzalex is not a cure guaranteed for every patient, and the appropriate regimen must be determined by the treating specialist.

Side Effects and Important Safety Information

Darzalex may cause side effects, and patients should receive the official prescribing information before treatment. Commonly reported adverse reactions can include fatigue, nausea, fever, cough, respiratory infections, low blood-cell counts and infusion-related reactions.

Serious risks may include severe hypersensitivity reactions, infections, low blood counts and interference with certain blood compatibility testing. Healthcare professionals should be informed that the patient is receiving daratumumab before blood transfusions are arranged.

Patients should disclose existing medical conditions, current medicines, pregnancy status and any previous allergic reactions to their healthcare provider. Breathing difficulties, facial swelling, severe allergic symptoms or other serious reactions require immediate medical attention.

Important: Darzalex must be administered under medical supervision. Do not self-administer this medicine or change the prescribed treatment schedule without specialist advice.

Frequently Asked Questions (FAQs)

1. What is Darzalex 400 mg Injection used for?

Darzalex contains daratumumab and is used in approved treatment regimens for multiple myeloma in eligible adults. The specific indication depends on the patient's circumstances and the applicable national prescribing information.

2. How does Darzalex work?

Daratumumab binds to the CD38 protein on multiple myeloma cells and promotes immune-mediated mechanisms that help destroy these cells.

3. How is Darzalex 400 mg administered?

The intravenous formulation is administered by qualified healthcare professionals. Dosage, infusion schedule and accompanying medicines depend on the prescribed treatment regimen.

4. What are the common side effects?

Possible side effects include fatigue, nausea, fever, cough, infections, reduced blood-cell counts and infusion-related reactions. Consult the prescribing information for complete safety details.

5. How can I enquire about Darzalex 400 mg supply?

Contact Cordium Pharmaceuticals Pvt Ltd to enquire about product availability, documentation and supply requirements. All supply arrangements are subject to applicable pharmaceutical regulations, product authorization and destination-country import requirements.

Enquire About Darzalex 400 mg Injection

Cordium Pharmaceuticals Pvt Ltd welcomes qualified pharmaceutical trade and institutional enquiries regarding product information and potential supply arrangements. Contact the company for verified product specifications, applicable documentation and market-specific availability.

Medical disclaimer: This webpage is for general informational purposes only and does not replace professional medical advice or the official prescribing information. Darzalex is a prescription medicine. Availability, approved indications and distribution requirements vary by country.